Sodium Glucose Transporter-2 Inhibitors (Sglt2is)-Tlrs Axis Modulates Diabetes Publisher Pubmed



Niknejad A^{1, 2} ; Hosseini Y^{1, 2} ; Shamsnia HS^{1, 2} ; Kashani AS^{1, 2} ; Rostamian F^{1, 2} ; Momtaz S^{2, 3, 4} ; Abdolghaffari AH^{1, 2} Show Affiliations
Source: Cell Biochemistry and Biophysics Published:2023

Abstract

Diabetes affects millions of people worldwide and is mainly associated with impaired insulin function. To date, various oral anti-diabetic drugs have been developed, of which, the sodium glucose transporter-2 inhibitors (SGLT2Is) are of the most recent classes that have been introduced. They differ from other classes in terms of their novel mechanism of actions and unique beneficial effects rather than just lowering glucose levels. SGLT2Is can protect body against cardiovascular events and kidney diseases even in non-diabetic individuals. SGLT2Is participate in immune cell activation, oxidative stress reduction, and inflammation mediation, thereby, moderating diabetic complications. In addition, toll like receptors (TLRs) are the intermediators of the immune system and inflammatory process, thus it’s believed to play crucial roles in diabetic complications, particularly the ones that are related to inflammatory reactions. SGLT2Is are also effective against diabetic complications via their anti-inflammatory and oxidative properties. Given the anti-inflammatory properties of TLRs and SGLT2Is, this review investigates how SGLT2Is can affect the TLR pathway, and whether this could be favorable toward diabetes. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.